IceCure Medical (ICCM) has submitted a regulatory filing with China’s National Medical Products Administration for the approval of its ProSense Cryoablation System. IceCure’s IceSense3, its predecessor cryoablation system, already has regulatory approval in China. The indicated use for ProSense in China is as a cryosurgical tool in the fields of general surgery including breast tissue, dermatology, thoracic surgery including lung tissue, gynecology, oncology, proctology, and urology including kidney tissue.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- Icecure Medical Announces Equity Distribution Agreement
- IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025
- IceCure Medical Regains Nasdaq Compliance, Securing Market Position
- IceCure Medical regains Nasdaq compliance
- IceCure Medical Secures European Patent for Next-Generation Cryoablation Technology